Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review
Abstract Current therapies for Parkinson’s disease (PD) are palliative, of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration. Due to the complication of such a multifactorial disorder and significant limitations of the ther...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Translational Neurodegeneration |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40035-020-00226-x |
id |
doaj-586e4cd574e94d2399beff429a35db59 |
---|---|
record_format |
Article |
spelling |
doaj-586e4cd574e94d2399beff429a35db592021-01-17T12:58:13ZengBMCTranslational Neurodegeneration2047-91582021-01-0110111310.1186/s40035-020-00226-xCross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive reviewTapan Behl0Gagandeep Kaur1Ovidiu Fratila2Camelia Buhas3Claudia Teodora Judea-Pusta4Nicoleta Negrut5Cristiana Bustea6Simona Bungau7Chitkara College of Pharmacy, Chitkara UniversityChitkara College of Pharmacy, Chitkara UniversityDepartment of Medical Disciplines, Faculty of Medicine and Pharmacy, University of OradeaDepartment of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of OradeaDepartment of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of OradeaDepartment of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of OradeaDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of OradeaDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of OradeaAbstract Current therapies for Parkinson’s disease (PD) are palliative, of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration. Due to the complication of such a multifactorial disorder and significant limitations of the therapy, numerous genetic approaches have been proved effective in finding out genes and mechanisms implicated in this disease. Following the observation of a higher frequency of PD in Gaucher’s disease (GD), a lysosomal storage condition, mutations of glycosylceramidase beta (GBA) encoding glucocerebrosidase (GCase) have been shown to be involved and have been explored in the context of PD. GBA mutations are the most common genetic risk factor of PD. Various studies have revealed the relationships between PD and GBA gene mutations, facilitating a better understanding of this disorder. Various hypotheses delineate that the pathological mutations of GBA minimize the enzymatic activity of GCase, which affects the proliferation and clearance of α-synuclein; this affects the lysosomal homeostasis, exacerbating the endoplasmic reticulum stress or encouraging the mitochondrial dysfunction. Identification of the pathological mechanisms underlying the GBA-associated parkinsonism (GBA + PD) advances our understanding of PD. This review based on current literature aims to elucidate various genetic and clinical characteristics correlated with GBA mutations and to identify the numerous pathological processes underlying GBA + PD. We also delineate the therapeutic strategies to interfere with the mutant GCase function for further improvement of the related α-synuclein–GCase crosstalks. Moreover, the various therapeutic approaches such as gene therapy, chaperone proteins, and histone deacetylase inhibitors for the treatment of GBA + PD are discussed.https://doi.org/10.1186/s40035-020-00226-xParkinson’s diseaseGlycosylceramidaseGlucocerebrosidaseGaucher’s diseaseMutationsα-Synuclein |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tapan Behl Gagandeep Kaur Ovidiu Fratila Camelia Buhas Claudia Teodora Judea-Pusta Nicoleta Negrut Cristiana Bustea Simona Bungau |
spellingShingle |
Tapan Behl Gagandeep Kaur Ovidiu Fratila Camelia Buhas Claudia Teodora Judea-Pusta Nicoleta Negrut Cristiana Bustea Simona Bungau Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review Translational Neurodegeneration Parkinson’s disease Glycosylceramidase Glucocerebrosidase Gaucher’s disease Mutations α-Synuclein |
author_facet |
Tapan Behl Gagandeep Kaur Ovidiu Fratila Camelia Buhas Claudia Teodora Judea-Pusta Nicoleta Negrut Cristiana Bustea Simona Bungau |
author_sort |
Tapan Behl |
title |
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review |
title_short |
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review |
title_full |
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review |
title_fullStr |
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review |
title_full_unstemmed |
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review |
title_sort |
cross-talks among gba mutations, glucocerebrosidase, and α-synuclein in gba-associated parkinson’s disease and their targeted therapeutic approaches: a comprehensive review |
publisher |
BMC |
series |
Translational Neurodegeneration |
issn |
2047-9158 |
publishDate |
2021-01-01 |
description |
Abstract Current therapies for Parkinson’s disease (PD) are palliative, of which the levodopa/carbidopa therapy remains the primary choice but is unable to modulate the progression of neurodegeneration. Due to the complication of such a multifactorial disorder and significant limitations of the therapy, numerous genetic approaches have been proved effective in finding out genes and mechanisms implicated in this disease. Following the observation of a higher frequency of PD in Gaucher’s disease (GD), a lysosomal storage condition, mutations of glycosylceramidase beta (GBA) encoding glucocerebrosidase (GCase) have been shown to be involved and have been explored in the context of PD. GBA mutations are the most common genetic risk factor of PD. Various studies have revealed the relationships between PD and GBA gene mutations, facilitating a better understanding of this disorder. Various hypotheses delineate that the pathological mutations of GBA minimize the enzymatic activity of GCase, which affects the proliferation and clearance of α-synuclein; this affects the lysosomal homeostasis, exacerbating the endoplasmic reticulum stress or encouraging the mitochondrial dysfunction. Identification of the pathological mechanisms underlying the GBA-associated parkinsonism (GBA + PD) advances our understanding of PD. This review based on current literature aims to elucidate various genetic and clinical characteristics correlated with GBA mutations and to identify the numerous pathological processes underlying GBA + PD. We also delineate the therapeutic strategies to interfere with the mutant GCase function for further improvement of the related α-synuclein–GCase crosstalks. Moreover, the various therapeutic approaches such as gene therapy, chaperone proteins, and histone deacetylase inhibitors for the treatment of GBA + PD are discussed. |
topic |
Parkinson’s disease Glycosylceramidase Glucocerebrosidase Gaucher’s disease Mutations α-Synuclein |
url |
https://doi.org/10.1186/s40035-020-00226-x |
work_keys_str_mv |
AT tapanbehl crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview AT gagandeepkaur crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview AT ovidiufratila crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview AT cameliabuhas crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview AT claudiateodorajudeapusta crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview AT nicoletanegrut crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview AT cristianabustea crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview AT simonabungau crosstalksamonggbamutationsglucocerebrosidaseandasynucleiningbaassociatedparkinsonsdiseaseandtheirtargetedtherapeuticapproachesacomprehensivereview |
_version_ |
1724334148891443200 |